Contact Us

RECOVER is a clinical study for people who are about to start their first treatment for breast cancer. The purpose of this study is to compare eflapegrastim and pegfilgrastim (also known as Neulasta®*) while you receive TC chemotherapy for early-stage breast cancer, by collecting blood samples and will be looking at the number of white blood cells, including neutrophils, being produced by the body.

*Disclaimer Third Parties

All product and company names are trademarks (TM) or registered trademarks (®) of their respective holders. Use of them does not imply any affiliation, approval, license or endorsement by them.

Neulasta® is a registered trademark of Amgen Inc.

Terms of Use

Privacy Policy

Web Site Linking Policy

Eflapegrastim (also known as SPI-2012) is a medication currently being tested and has yet to receive approval from the Food and Drug Administration (FDA).

© 2017 Spectrum Pharmaceuticals, Inc. All Rights Reserved.